Corcept Therapeutics Inc. (CORT) Dividend History

Company News

• High- and Low-Grade Serous Ovarian Cancer Market is Predicted to Grow at a CAGR of 7.9% During the Study Period (2020–2034) | DelveInsight

  The global high- and low-grade serous ovarian cancer market is expected to grow at a CAGR of 7.9% from 2020 to 2034, driven by the launch of emerging therapies. The US market is the largest, capturing nearly USD 1.9 billion in 2024. Key companies working on innovative ovarian cancer drugs include Verastem Oncology, Corcept Therapeutics, AstraZeneca, and others.

  GlobeNewswire Inc.
• Corcept Moves 6.5% Higher: Will This Strength Last?

  Corcept Therapeutics shares soared 6.5% due to strong demand for its drug Korlym and the expected filing of a new drug application for its lead candidate relacorilant. The company's earnings and revenue growth expectations also contribute to the share price rally.

  Benzinga

  Featured Companies: ZTS
• Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

  The First Trust NYSE Arca Biotechnology ETF (FBT) is a passively managed exchange-traded fund that provides broad exposure to the healthcare-biotech sector. The ETF tracks the NYSE Arca Biotechnology Index and has a relatively high expense ratio of 0.56%. Its top holdings include Alnylam Pharmaceuticals, Corcept Therapeutics, and United Therapeutics.

  Zacks Investment Research

  Featured Companies: ALNY FBT IBB UTHR XBI